Capricor Therapeutics Receives FDA Advisory Committee Meeting Date for Deramiocel

What happened

The U.S. Food and Drug Administration scheduled an advisory committee meeting for July 29, 2026 to discuss Capricor Therapeutics' Biologics License Application for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) will review the application, which is supported by data from the Phase 2 HOPE-2 trial, its long-term open-label extension (HOPE-2-OLE), and the Phase 3 HOPE-3 trial. The HOPE-3 trial met its primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF) with statistical significance. The FDA's PDUFA target action date for the application remains August 22, 2026. The meeting will be publicly live-streamed.

Why it matters

This advisory committee meeting represents a critical regulatory milestone in Capricor's effort to bring Deramiocel to market as a potential first-in-class therapy for DMD, a severe genetic muscle disorder affecting approximately 15,000 individuals in the United States with no current cure. The scheduling of the meeting indicates the FDA is proceeding with its review on track with the PDUFA date. Advisory committee meetings allow the FDA to gather expert input on complex applications, particularly for novel therapies like cell-based treatments. A positive committee recommendation, while not binding, typically improves approval prospects. Deramiocel has received multiple regulatory designations including Orphan Drug, Regenerative Medicine Advanced Therapy (RMAT), and Rare Pediatric Disease status, which may qualify Capricor for a Priority Review Voucher upon approval.

Bigger picture

Duchenne muscular dystrophy remains an area of significant unmet medical need, with progressive muscle degeneration leading to cardiomyopathy and heart failure as the primary cause of death. Current treatment options are limited. Deramiocel represents a novel approach using allogeneic cardiosphere-derived cells that have demonstrated anti-fibrotic and immunomodulatory effects in preserving cardiac and skeletal muscle function. The therapy has been administered to over 250 human subjects across clinical trials with a favorable safety profile. The five-year HOPE-2 OLE data showed sustained benefit, with patients experiencing mean PUL 2.0 score decline of less than 5 points over five years, compared to an estimated 12-point decline in standard-of-care matched comparators. Cardiac function measured by LVEF remained stable over the full period, contrasting with modeled annual declines of 3.2% in external comparators.

What to watch

The key near-term catalyst is the July 29, 2026 advisory committee meeting, where Capricor will present its clinical evidence and safety data to the panel of FDA advisors. Investors should monitor the committee's discussion, questions raised about efficacy durability and safety, and any voting outcome or recommendation. The meeting will be publicly accessible via live stream. Following the advisory meeting, attention will shift to the August 22, 2026 PDUFA date, when the FDA is scheduled to complete its review and issue an approval decision. Successful navigation of both the advisory committee and final FDA review could position Deramiocel as the first approved cell therapy for DMD and potentially generate a Priority Review Voucher for Capricor.